Tag Archives: sclerostin
Interplay of sclerostin and cytokines of interleukin-6 family in the pathophysiology of coronary artery disease
S. S. Rozoqi1, T. A. Allwsh2*
1Department of Medical Laboratory Technology,
Erbil Technical Health and Medical College, Erbil Polytechnic University, Erbil, Iraq;
2Department of Chemistry, Collage of Science, University of Mosul, Mosul, Iraq
*e-mail: thekraaliallwsh@uomosul.edu.iq
Received: 09 June 2025; Revised: 25 September 2025;
Accepted: 30 January 2026; Available on-line: 23 February 2026
Sclerostin, a Wnt/β-catenin signaling antagonist, plays a predominant role in bone metabolism and is also expressed in cardiovascular tissues. The level of this glycoprotein is associated with aortic stiffness and vascular calcification in coronary artery disease (CAD). Our study explored the relationship between the levels of sclerostin, cytokines of interleukin-6 family and prostaglandin E2 (PGE2) in the blood serum of CAD patients. The study included two groups of patients : 80 patients aged 46-74 with a stable coronary heart disease, and 80 patients aged 46-70 as a control group. The levels of oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1) and prostaglandin E2 (PGE2) were estimated with ELISA. The result have shown a highly significant decrease of sclerostin in conjunction with the increase of OSM, CT-1, LIF levels and along with the decrease of PGE2 level in the serum of patient with CAD comparing with control group. Pearson correlation analysis showed a significant relationship between sclerostin and OSM, CT-1, LIF, PGE2 concentrations. ROC curve analysis indicated that patients at risk for coronary heart disease could be identified with a specificity of 0.975 when their serum sclerostin level was greater than 88.325 pg/ml. Therefore, sclerostin could play a critical role in CAD and may be useful for monitoring disease progression.
Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
F. F. Rija1, S. Z. Hussein2*, M. A. Abdalla3
1Department of Biology, Tikrit University – College of Sciences, Tikrit, Iraq;
2Clinical Biochemistry Unit, Salah Aldeen Health Directorate, Tikrit, Iraq;
3Department of Human Anatomy, Tikrit University College of Medicine, Tikrit, Iraq;
*e-mail: drmohammadahmad68@gmail.com
Received: 15 February 2021; Accepted: 22 September 2021
The maintenance of thyroid hormone homeostasis is essential in the regulation of skeletal system development, bone tissue mineralization and fracture risk prevention. This study was carried out to evaluate the serum level of osteoprotegerin (OPG), sclerostin (SOST), and osteocalcin (OC) in hypo- and hyperthyroidism patients. A total number of examined patients was 90 individuals, 30 of them were normal as a control group, the rest 60 individuals were arranged in two groups: 30 patients with hypothyroidism and 30 patients with hyperthyroidism. Serum assay tests for OPG, SOST, OC, thyroid stimulating hormone (TSH), total triiodothyronine (T3), and total thyroxine (T4) were used. The present study reported high levels of SOST, T3, and T4 and low levels of OPG, OC, and TSH in patients with hyperthyroidism compared to control. Whereas in patients with hypothyroidism only SOST and TSH levels were increased, but OPG, OC, T3, and T4 levels were low compared to control. The data obtained indicate the correlation on osteoprotegerin, sclerostin, and osteocalcin levels with thyroid hormones disturbances.